NCT01021995 is a Phase 4 clinical trial of echinacea in Infections, sponsored by A. Vogel AG.

Who is sponsoring NCT01021995?

NCT01021995 is sponsored by A. Vogel AG.

What drugs are being tested in NCT01021995?

Interventions in NCT01021995: echinacea, placebo.

What condition does NCT01021995 study?

NCT01021995 studies Infections.

Is NCT01021995 still recruiting?

NCT01021995 is currently completed. Last updated 22 July 2014.

Last reviewed 2014-07-22 · How we verify

NCT01021995

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Safety and Efficacy of Long-term Treatment With Echinaforce® Over 4 Months

Completed Phase 4 Last updated 22 July 2014

What this trial tests

Phase 4 trial testing echinacea in Infections in 757 participants. Completed in 1 April 2011.

Timeline

1 October 2009

Primary endpoint
1 August 2010

1 April 2011

Quick facts

Lead sponsor	A. Vogel AG
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	prevention
Enrollment	757
Start date	1 October 2009
Primary completion	1 August 2010
Estimated completion	1 April 2011
Sites	1 location across United Kingdom

Drugs / interventions tested

echinacea — full drug profile →
placebo

Conditions studied

Infections — all drugs for Infections →

Sponsor

A. Vogel AG — full company profile →

Who can join

18 and older, any sex, with Infections. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Occurrence of Adverse Drug Reactions
Time frame: 4 months

Sponsor's own description

Extracts produced from Echinacea purpurea are traditionally used for the prevention and the acute treatment of influenzal infections like the common cold. The aim of this clinical study is to assess clinical safety and efficacy of a treatment with Echinacea in comparison to placebo. 750 healthy subjects with a history of equal or more than 2 cold episodes per year will be recruited during October and November 2009 and will be treated with either Echinacea or placebo over a period of 4 months. Throughout the study period adverse events (AEs) and adverse drug reactions (AEs with at least a possible causal relation to the treatment) will be recorded. Common cold related symptoms will be recorded in a daily diary.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Infections

Currently open trials in the same condition.

NCT07512141 — Single Versus Double Drains in the Axillary and Pectoral Regions After Modified Radical Mastectomy · NA · recruiting
NCT07189858 — Light-Activated Antimicrobial Therapy to Prevent Surgical Site Infections - Canada · NA · active not recruiting
NCT06426147 — L-citrulline to Improve Adverse Outcomes in Admitted Children (EChiLiBRiST, Clinical Trial 2, Inpatients) · NA · recruiting
NCT06911658 — Infectious Complications After Esophagectomy · recruiting
NCT06145724 — EnCoRe MoMS: Engaging Communities to Reduce Morbidity From Maternal Sepsis (Aim 1) · NA · recruiting

Other A. Vogel AG trials

Trials by the same sponsor.

NCT06795776 — Eschscholzia Study · Phase 3 · completed
NCT05748574 — Sleep Well Observation Study · NA · completed
NCT05757050 — Mental Balance Study · NA · completed
NCT04999098 — Echinaforce COVID-19 Shedding Study · Phase 4 · terminated
NCT05002179 — Echinaforce Study to Investigate Explorative Pharmacology and Effectiveness to Prevent From Enveloped Virus Infections · Phase 4 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01021995 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by A. Vogel AG
Last refreshed: 22 July 2014

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01021995.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing